抗体治療  [in Japanese] Antibody treatment  [in Japanese]

Access this Article

Author(s)

    • 佐々木 茂 Sasaki Shigeru
    • 札幌医科大学医学部 消化器・免疫・リウマチ内科学講座 Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University
    • 篠村 恭久 Shinomura Yasuhisa
    • 札幌医科大学医学部 消化器・免疫・リウマチ内科学講座 Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University

Abstract

今から30年ほど前に抗体治療を目指しさまざまに苦闘されていた諸先輩は、現在の抗体医薬の進歩を予想されたであろうか。現在、抗体医薬の守備範囲は、当初想定されていた悪性腫瘍にとどまらず、関節リウマチや全身性エリテマトーデスをはじめとした自己免疫性疾患、気管支喘息などのアレルギー疾患、炎症性腸疾患や神経疾患、そして骨粗鬆症など多岐にわたり、その有効性が探られ報告されている。本稿では、おもに悪性腫瘍に対する抗体医薬の進歩を概説するとともに、今や、治療体系の主体をなしてきている関節リウマチや炎症性腸疾患における抗体医薬の位置づけや治療薬に関しても触れていきたいと思う。

Thirty years ago, our forerunners spent thousands of hours aiming to realize antibody treatments. Would they ever have been able to imagine the advances in antibody treatments that we see today? Currently, antibody drugs cover not only malignant neoplasms but also autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus; allergic diseases such as bronchial asthma; inflammatory bowel diseases (IBD); neurological diseases; and osteoporosis: their effectiveness in these disorders have been investigated and reported. In this review, we will review the advances particularly in those against malignancies. We will also allude to their position in the treatments of RA and IBD, where now these drugs are the mainstays, and also to individual agents.

Journal

  • Drug Delivery System

    Drug Delivery System 30(1), 16-24, 2015

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

Codes

  • NII Article ID (NAID)
    130005066112
  • NII NACSIS-CAT ID (NCID)
    AN10084591
  • Text Lang
    JPN
  • ISSN
    0913-5006
  • NDL Article ID
    026049466
  • NDL Call No.
    Z19-1945
  • Data Source
    NDL  J-STAGE 
Page Top